Caissa Capital Management ltd. - 12 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
12 Jun 2023
Net transactions value
+$63,629
Form type
4
Filing time
14 Jun 2023, 16:14:07 UTC
Previous filing
09 Jun 2023
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $9,316 +2,149 +0.15% $4.34* 1,402,790 12 Jun 2023 See Footnote (1) F1, F2
transaction AVTX Common Stock Purchase $33,439 +8,750 +0.62% $3.82* 1,411,540 13 Jun 2023 See Footnote (1) F1, F3
transaction AVTX Common Stock Purchase $20,874 +6,000 +0.43% $3.48* 1,417,540 14 Jun 2023 See Footnote (1) F1, F4
holding AVTX Common Stock 182,300 12 Jun 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.125 to $4.47, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7 to $3.83, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.245 to $3.55, inclusive.
F5 These shares are directly owned by Mr. Golestaneh in his personal capacity.